Placebo to match LY, PEMBROLIZUMAB , DURVALUMAB
J3M-MC-JZQH
Phase 3 small_molecule active
Quick answer
Placebo to match LY, PEMBROLIZUMAB , DURVALUMAB for Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active